Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
No change to hypertension management; leaves open whether combined dyslipidemia-RAS blockade improves outcomes.
Dyslipidemia and hypertension are frequently observed in patients with ischemic heart disease. Studies from a number of laboratories suggest up-regulation of different components of the renin-angiotensin system (RAS) in patients with hypertension and atherosclerosis. Lipid accumulation in the blood vessels enhances the expression of RAS components; on the other hand, activation of RAS stimulates accumulation of low-density lipoproteins, particularly the oxidatively modified form, in the blood vessels. This concept of cross-talk between dyslipidemia and RAS activation has been proven in laboratory-based studies. Clinical trials also suggest that blockade of dyslipidemia and RAS may have a synergistic salutary effect on the outcome of patients with hypertension and/or manifestations of atherosclerosis. This concept needs to be evaluated in large clinical studies.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: